Evidence mapPaperPMID 40293161Full record

ReviewMicrobial biotechnology2025

The Respiratory Tract Microbiome and Human Health.

Patricia Fernández de Córdoba-Ansón, Iván Linares-Ambohades, Fernando Baquero, Teresa M Coque, Ana Elena Pérez-Cobas

Abstract readReview
In one paragraph

Review in Microbial biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Palmitoleic acid loss links pulmonary dysbiosis to lung injury after single-lung ventilation.American journal of respiratory cell and molecular biology · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Patricia Fernández de Córdoba-AnsónDepartment of Microbiology, Ramón y Cajal Institute for Health Research (IRYCIS), Ramón y Cajal University Hospital, Madrid, Spain.ORCID https://orcid.org/0009-0006-9681-9695
Iván Linares-AmbohadesDepartment of Microbiology, Ramón y Cajal Institute for Health Research (IRYCIS), Ramón y Cajal University Hospital, Madrid, Spain.ORCID https://orcid.org/0009-0007-2700-2494
Fernando BaqueroDepartment of Microbiology, Ramón y Cajal Institute for Health Research (IRYCIS), Ramón y Cajal University Hospital, Madrid, Spain.ORCID https://orcid.org/0000-0002-7930-3033
Teresa M CoqueDepartment of Microbiology, Ramón y Cajal Institute for Health Research (IRYCIS), Ramón y Cajal University Hospital, Madrid, Spain.ORCID https://orcid.org/0000-0002-8228-3491
Ana Elena Pérez-CobasDepartment of Microbiology, Ramón y Cajal Institute for Health Research (IRYCIS), Ramón y Cajal University Hospital, Madrid, Spain.ORCID https://orcid.org/0000-0002-3995-5571

Funding

Comunidad de Madrid 2023-T1/SAL-GL28953Comunidad de Madrid PEJ-2024-AI/SAL-GL-31755Instituto de Salud Carlos III PI23/01036
6 · The paper itself

Abstract

The respiratory tract microbiome (RTM) is a multi-kingdom microbial ecosystem that inhabits various niches of the respiratory system. While previously overlooked, there is now sufficient evidence that the RTM plays a crucial role in human health related to immune system training and protection against pathogens. Accordingly, dysbiosis or disequilibrium of the RTM has been linked to several communicable and non-communicable respiratory diseases, highlighting the need to unveil its role in health and disease. Here, we define the RTM and its place in microbiome medicine. Moreover, we outline the challenges of RTM research, emphasising the need for combining methodologies, including multi-omics and computational tools. We also discuss the RTM's potential for diagnosing, preventing and treating respiratory diseases and developing novel microbiome-based therapies to improve pulmonary health.

Indexed as

MicrobiotaRespiratory SystemRespiratory Tract DiseasesDysbiosisHumanshuman healthmethods in microbiome researchmicrobiome‐based therapiesmicrobiome biotechnologyrespiratory tract microbiome

Identifiers

PMID40293161
PMCPMC12035874

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.